Shelly Kalaora

1.5k total citations · 1 hit paper
8 papers, 447 citations indexed

About

Shelly Kalaora is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Shelly Kalaora has authored 8 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Immunology and 4 papers in Oncology. Recurrent topics in Shelly Kalaora's work include Immunotherapy and Immune Responses (6 papers), vaccines and immunoinformatics approaches (4 papers) and Peptidase Inhibition and Analysis (2 papers). Shelly Kalaora is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), vaccines and immunoinformatics approaches (4 papers) and Peptidase Inhibition and Analysis (2 papers). Shelly Kalaora collaborates with scholars based in Israel, United States and Netherlands. Shelly Kalaora's co-authors include Yardena Samuels, Adi Nagler, Jennifer A. Wargo, Arie Admon, Steven A. Rosenberg, Eilon Barnea, Michal Alon, Michal J. Besser, Jacob Schachter and Nouar Qutob and has published in prestigious journals such as Nature Communications, Nature reviews. Cancer and Cell Reports.

In The Last Decade

Shelly Kalaora

8 papers receiving 443 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of immune activation and regulation: lessons from melanoma

2022 149 citations Shelly Kalaora, Adi Nagler et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Shelly Kalaora

Since Specialization

Citations

This map shows the geographic impact of Shelly Kalaora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shelly Kalaora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shelly Kalaora more than expected).

Fields of papers citing papers by Shelly Kalaora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shelly Kalaora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shelly Kalaora. The network helps show where Shelly Kalaora may publish in the future.

Co-authorship network of co-authors of Shelly Kalaora

This figure shows the co-authorship network connecting the top 25 collaborators of Shelly Kalaora. A scholar is included among the top collaborators of Shelly Kalaora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shelly Kalaora. Shelly Kalaora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	Mechanisms of immune activation and regulation: lessons from melanoma breakdown → 2022 ·Nature reviews. Cancer ·Shelly Kalaora, Adi Nagler, Jennifer A. Wargo, Yardena Samuels	149
2	Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics 2021 ·Cell Reports ·Adi Nagler, Shelly Kalaora, Chaya Barbolin, Anastasia Gangaev, Steven L. C. Ketelaars, Michal Alon, Joy A. Pai, Gil Benedek, Yfat Yahalom-Ronen, Noam Erez, Polina Greenberg, Gal Yagel, (unknown), Yishai Levin, Ansuman T. Satpathy, Erez Bar‐Haim, Nir Paran, Pia Kvistborg, Yardena Samuels	35
3	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma 2020 ·Nature Communications ·Shelly Kalaora, Joo Sang Lee, Eilon Barnea, Ronen Levy, Polina Greenberg, Michal Alon, Gal Yagel, (unknown), Roni Oren, (unknown), Sushant Patkar, (unknown), Steven A. Rosenberg, Michal Lotem, Yishai Levin, Arie Admon, Eytan Ruppin, Yardena Samuels	106
4	A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma 2019 ·Pigment Cell & Melanoma Research ·Adi Nagler, David W. Vredevoogd, Michal Alon, Phil F. Cheng, (unknown), Shelly Kalaora, Rand Arafeh, (unknown), Mitchell P. Levesque, Daniel S. Peeper, Yardena Samuels	19
5	Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry 2018 ·Methods in molecular biology ·Shelly Kalaora, Yardena Samuels	5
6	CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma 2018 ·Oncotarget ·Michal Alon, Rand Arafeh, (unknown), Sanna Madan, Shelly Kalaora, Adi Nagler, (unknown), Polina Greenberg, Eytan Ruppin, Yardena Samuels	11
7	24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma 2018 ·ESMO Open ·Shelly Kalaora, Yochai Wolf, Alexandre Reuben, Steven A. Rosenberg, Michal Lotem, Uğur Şahin, Jennifer A. Wargo, Nir Friedman, Arie Admon, Yardena Samuels	13
8	Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens 2016 ·Oncotarget ·Shelly Kalaora, Eilon Barnea, Efrat Merhavi-Shoham, Nouar Qutob, Jamie K. Teer, (unknown), Jacob Schachter, Steven A. Rosenberg, Michal J. Besser, Arie Admon, Yardena Samuels	109

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact